Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

A self-assembled nano micelle-exosome with high selectivity and penetrability achieves precise intracartilage lipid delivery

Li MY., Wu LM., Xie HQ., Shen B.

Animal Study on Osteoarthritis, published in Sci Adv (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Sci Adv (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41348870
PMCID
PMC12680035
DOI
10.1126/sciadv.adv8999
Citations
3

Abstract (original English)

To address the challenge of extremely low drug bioavailability in osteoarthritis (OA) cartilage, we developed a self-assembled micelle-exosome system (Mic-Exo) tailored to the specific characteristics of OA cartilage. The hydrophobic lipid layer of Mic-Exo enables efficient loading of therapeutic lipids (DHA), while the incorporation of 1, 2-dioleoyl-3-trimethylammonium-propane (DOTAP) reverses surface charge to enhance penetration. The hydrophilic polyethylene glycol (PEG) shell protects Mic-Exo from rapid clearance and undesired endocytosis. The amphiphilic monomers in the micelle incorporate a matrix metalloproteinase (MMP)-responsive peptide (GPLGVRG), which undergoes hydrolysis in response to elevated MMP activity at lesion sites, enabling rapid uptake by nearby chondrocytes. In vitro experiments confirmed the high selectivity of Mic-Exo for OA chondrocytes and its rapid penetration capabilities. In animal models, the DHA/Mic-Exo group significantly retarded OA progression, as evidenced by reduced Osteoarthritis Research Society International (OARSI) scores and mitigated cartilage thickness loss.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
ChondrocytesAnimalsHumansOsteoarthritisDisease Models, AnimalPolyethylene GlycolsLipidsDrug CarriersDrug Delivery SystemsMicelles

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research